Study S000185

Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01208012
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 44
Start: 2010-04
Primary completion: 2010-11
Lead sponsor: ikfe-CRO GmbH
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Victoza®
Results posted: FALSE

Registered primary outcomes

The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells [timepoint 0 and after 6 and 12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0027141	Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Forst T, Diabetic medicine : a journal of the British Diabetic Association	2012	Randomized trial	PMID 22288732 DOI	cites ClinicalTrials.gov:NCT01208012; registry reference DERIVED:22288732